Global Pharmaceuticals & Biotech ROE over 20

Johnson & Johnson

Market Cap: US$557.8b

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Gilead Sciences

Market Cap: US$162.0b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Bristol-Myers Squibb

Market Cap: US$121.6b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Vertex Pharmaceuticals

Market Cap: US$110.0b

Operates as a biotechnology company in the United States, Europe, and internationally.

IQVIA Holdings

Market Cap: US$28.0b

Provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

United Therapeutics

Market Cap: US$24.0b

Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Illumina

Market Cap: US$21.9b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Incyte

Market Cap: US$19.5b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Exelixis

Market Cap: US$12.5b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Liquidia

Market Cap: US$5.5b

A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.

Catalyst Pharmaceuticals

Market Cap: US$3.8b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

ACADIA Pharmaceuticals

Market Cap: US$3.7b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Organon

Market Cap: US$3.5b

Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

ADMA Biologics

Market Cap: US$2.0b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Innoviva

Market Cap: US$1.6b

Operates as a biopharmaceutical company in the United States and internationally.

Phibro Animal Health

Market Cap: US$1.4b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Anbio Biotechnology

Market Cap: US$1.3b

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.

Collegium Pharmaceutical

Market Cap: US$1.1b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

Theravance Biopharma

Market Cap: US$842.4m

A biopharmaceutical company, develops and commercializes medicines in the United States.

CorMedix

Market Cap: US$632.3m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

XOMA Royalty

Market Cap: US$524.5m

Operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.

Abeona Therapeutics

Market Cap: US$314.6m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

Compugen

Market Cap: US$246.9m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Oramed Pharmaceuticals

Market Cap: US$177.2m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Vaxart

Market Cap: US$164.3m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.

Protalix BioTherapeutics

Market Cap: US$163.6m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

Spero Therapeutics

Market Cap: US$155.8m

A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.